Innovations in Vaccine Development for Emerging Viral Diseases

by

In the past few decades, new and virulent viral diseases have arisen that present important global public health threats. From SARS (severe acute respiratory syndrome) to Zika and currently the COVID-19 pandemic, these outbreaks by viral agents have certainly shown the necessity of rapidly developing an effective vaccine. Traditional vaccine development processes, often taking years or even decades, are too slow to respond to emerging threats. The other way around, rapid improvement in biotechnology, genomics, and artificial intelligence has changed the landscape of vaccine development and hence has made possible the creation and deployment of vaccines at incredible rates. The review article highlights the most relevant innovations in vaccine development against new and emerging viral diseases. The paper puts forth some of the current tools and modern approaches that have reshaped the entire process of vaccine development, testing, and distribution.

Messenger RNA Vaccine Technology Evolution

Over the last few years, one of the most radical innovations in vaccine development has been messenger RNA technology. Unlike the traditional vaccines built on inactivated or attenuated viruses, the mechanism of action for mRNA vaccines introduces a small genetic material of the virus itself into the body. In this way, this messenger RNA gives instructions so that the cells will produce a protein that will stimulate an immune response, something whereby, if the body sees that virus again in the future, it will teach the body how to recognize and fight it. The success of mRNA vaccines against COVID-19 has established a beacon regarding what this technology can do in a very short period of time for any other viral disease, if it evolves in the future. One reason that makes mRNA vaccine development significant is that they can be quickly designed and generated. mRNA vaccines are created within weeks once the genetic sequence of a virus is known, whereas traditional vaccine development takes years. Moreover, it does not require live virus cultures in the production process, which may get contaminated and hence simplify the process. 

Vaccine Design by AI and Machine Learning

Artificial intelligence and machine learning are an integral part of the new vaccine development process. They facilitate fast scanning through reams of biological data in search of possible vaccine targets. For example, AI algorithms could predict how a virus’s proteins will fold and interact with the immune system so that more effective vaccines could be designed.

AI has also been very instrumental in the optimization of formulations of vaccines and in making predictions of their efficacy. Machine learning models use past results from vaccine clinical trials to predict the performance of new candidates in different populations. This does not only cut down development time but increases the potential chances of success in clinical trials. Moreover, AI-driven platforms can simulate a myriad of scenarios for the prediction of how a virus might evolve, enabling researchers to stay one step ahead of potential mutations that could render vaccines less effective.

Yearwise Publication Trend on “vaccine development”

Find publication trends on relevant topics

The Role of Genomic Sequencing in Vaccine Development

Genomic sequencing has turned out to be a very essential weapon against novel viral diseases. The rapid genomic sequencing of viruses has given researchers critical information regarding their structure, evolution, and mechanisms of infection. This information becomes very instrumental in selecting the most effective vaccine targets, such as viral proteins that are essential for virus infectivity.

The role of genomic sequencing in the fight against pandemics was quite palpable during COVID-19. Within weeks of the identification of the first cases, scientists around the world had sequenced the SARS-CoV-2 genome, and diagnostic tests and vaccines were already in development. This knack for fast sequencing of the viral genome and sharing of information globally is setting a new standard in responses to emerging infectious diseases. It also keeps tabs on viral mutations, which is very important in updating vaccines to remain effective against evolving strains.

Advances in Vaccine Delivery Systems

Innovations in vaccine delivery systems have equally contributed to the enhancement of the efficacy and accessibility of vaccines. Traditional forms of the vaccine are usually injected, which somewhat makes it a barrier to vaccinating many people, especially in low-resource areas. In a bid to combat the challenge, researchers worked on alternative modes for vaccine delivery that are less invasive and more convenient to distribute.

One example of such innovation includes nanoparticle-based delivery systems. A system like that would help preserve vaccine-active ingredients from degradation and ensure they reach their target intact. Nanoparticles could be tailored to raise immune responses, thereby enhancing the effectiveness of vaccines. Developments in the microneedle patch and poster-sized vaccine systems applied to the skin without using a syringe now offer a painless, more far-reaching way of administering vaccines.

On top of this, vaccines are being developed in oral and intranasal routes that may totally avoid the use of needles. Such delivery methods shall not only facilitate vaccination per se but also induce a much more potent form of immune response along the mucosae, as seen for respiratory viruses like influenza and coronaviruses.

The Future of Vaccine Development,  Personalized Vaccines

The future of vaccine development is likely to reside in personalized vaccines informed by a deepening understanding of the immune system. These vaccines would take into account a person’s genetic makeup and medical history, even their microbiome, to create a vaccine optimized for their unique immune system.

In fact, it is already applied to cancer immunotherapy, where the development of a vaccine takes into account target mutations in the tumor patient’s . This approach can be developed for application in infectious diseases, whereby tailored vaccines against some circulating variety of a virus in a region or population would protect a person against certain viral strains. It would also be possible to use such vaccines in order to boost the effectiveness of vaccination in groups usually underrepresented among clinical trial subjects. For example, elderly people or people with a weak immune system.

Recent Publications on “vaccine development”

Find publications on relevant topics

Challenges and Ethical Considerations in Vaccine Development

These very innovations within vaccine development bring with them a host of challenges and ethical concerns. Keeping up with the fast pace of development and rollout, especially during a pandemic, requires robust regulatory frameworks that guarantee these vaccines safety and efficacy. Besides, frontline technologies like AI bring risks to data privacy and biased algorithms that may affect vaccine design.

Another challenge is having access to the vaccines fairly. Many inequities in the sharing of vaccines were pointed out by the COVID-19 pandemic, especially in low-income countries. They are suffering from delays in accessing COVID-19 vaccines. While new vaccines are being developed, such inequities should be dealt with, and all populations must be ensured life-saving immunizations.

Another issue that arises in developing personalized vaccines is cost and accessibility. While personalized medicine has the potential to revolutionize healthcare, it may also cause a chasm or a division amongst those who are able to afford advanced treatments, not all of which are equally accessible or possible to receive by everybody. That is the challenge for policymakers, healthcare providers, and the global community: to work out the means by which innovations in vaccine development help all of humanity and not just the privileged few.

Conclusion

Vaccines are undergoing a sea change, and at the moment, innovations in biotechnology, artificial intelligence, and genomic sequencing are just some of those drivers. Such technological advances have increased manifold the velocity at which new vaccines are developed to respond to emerging viral diseases, offering powerful tools against future global threats to human health. But as we continue to innovate, we must also collectively address new challenges and ethical considerations associated with these new technologies. This would ensure that gains from such an innovation are equitably shared amongst participants and that vaccines remain an effective way of winning the war against infectious diseases.

References

  1. Diao, S., Pan, R., Dong, H., Shum, K.S., Zhang, J., Xiong, W. and Zhang, T., 2023. Lmflow: An extensible toolkit for finetuning and inference of large foundation models. arXiv preprint arXiv:2306.12420.
  2. Nori, H., King, N., McKinney, S.M., Carignan, D. and Horvitz, E., 2023. Capabilities of gpt-4 on medical challenge problems. arXiv preprint arXiv:2303.13375.
  3. Pal, A., Umapathi, L.K. and Sankarasubbu, M., 2022, April. Medmcqa: A large-scale multi-subject multi-choice dataset for medical domain question answering. In Conference on health, inference, and learning (pp. 248-260). PMLR.
  4. Jin, Q., Dhingra, B., Liu, Z., Cohen, W.W. and Lu, X., 2019. Pubmedqa: A dataset for biomedical research question answering. arXiv preprint arXiv:1909.06146.
  5. Kissler, S.M., Tedijanto, C., Goldstein, E., Grad, Y.H. and Lipsitch, M., 2020. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science, 368(6493), pp.860-868.
  6. Jin, D., Pan, E., Oufattole, N., Weng, W.H., Fang, H. and Szolovits, P., 2021. What disease does this patient have? a large-scale open domain question answering dataset from medical exams. Applied Sciences, 11(14), p.6421.
  7. Lo, K., Wang, L.L., Neumann, M., Kinney, R. and Weld, D.S., 2019. S2ORC: The semantic scholar open research corpus. arXiv preprint arXiv:1911.02782.

Top Experts on “vaccine development“